Skip to content

ACNRF Annual Gala Dinner 2024

Date: Saturday 21 September 2024

Time: 6.30pm to 11.30pm

Shining a light of Hope for CASK, Igniting courage, progress, and the promise of a brighter tomorrow

Annual Gala Dinner 2024 Update

$64,000.00 total funds raised!

To each of our Donors and Sponsors, we extend our heartfelt thanks for your generous support of our ACNRF Annual Gala, raising funds for CASK Research. Your contribution has helped make this year’s event a resounding success, and we are deeply grateful for your commitment to advancing research and providing hope to families affected by CASK-related disorders.

Join us for a fantastic night at the Grand Roxy Brighton Le Sands raising funds for CASK Research.

**PURCHASE TICKETS BY 1 SEPTEMBER 2024 **

Price

$155.00* per person

Ticket Inclusions

  • 5 Course Dinner and Beverages
  • Music, dancing, live entertainment
  • Raffle Prizes
  • Auction

Dress Code

Formal

Business Sponsor Package $1550.00

Business Sponsor Packages Inclusions:

  • Tickets for 10 guests (1 table) to attend the event which includes (5 course dinner and beverages, music, live entertainment, raffle prizes and silent and live auction).
  • Recognition of the Sponsor in social media advertising the fundraising event.
  • The Sponsor’s logo to be displayed on our website as a supporter of ACNRF and as a Sponsor of the event.
  • The Sponsor’s logo to be included on our ‘thank you’ slideshow, which runs throughout the duration of the fundraising event.
  • Sponsor logo displayed on a table tent which will be placed on each table.
  • Large Banner presented with Sponsor’s logo to be displayed at the Fundraiser.
  • Should you wish to be a Sponsor and purchase this package please email us at admin@curecask.com with your logo. 

Location:

The Grand Roxy, 128 The Grand Parade Brighton Le Sands NSW.

Closest Parking: Novotel Brighton Car Park and side streets around venue

Novotel have kindly provided a 15% discount off accommodation for those  attending the Annual Gala  and wish to stay overnight.

Please contact us by email admin@curecask.com prior to booking the accommodation to receive the details on how to book to receive this discount.   

*If you have purchased individual tickets and wish to be seated with friends or family please email the relevant details so I can ensure you are seated together at admin@curecask.com* Tables are of 10 or 12 

*ticket price includes $50.00 donation*

Payment Options

Credit Card or PayPal


Direct Transfer/Deposit

If you wish to purchase your tickets or donate by way of Transfer/Direct Deposit please see below account details.

Please ensure you note your name in the reference details and email us at admin@curecask.com with details of your purchase so we can provide you with a receipt.

ANGELINA CASK NEUROLOGICAL RESEARCH FOUNDATION LTD.

BSB: 082-057

Account Number: 56-374-9648

Should you not see an email from us confirming your purchase please check your JUNK EMAIL!

Thank you to our Gold Sponsors

United Commercial & Residential
AMSGL

Thank you to our Silver Sponsors

DONATE AUSTRALIA
DONATE USA
SHOP AUSTRALIA
SHOP USA

Lavvina Thiyagarajan

MBBS

Lavvina is a clinical genetics fellow from NSW, Australia with a background in general paediatrics. She has practiced in multiple tertiary paediatric hospitals in Australia, both in general paediatrics and clinical genetics. She currently provides specialist advice for the NGO, Taking Paediatrics Abroad and is a member of GeneEQUAL, an inclusive research group aiming to improve accessibility of genetic testing and care for people with intellectual disability by co-design.

Lavvina’s clinical interests are in the genetics of autism, intellectual disability and immunogenomics. She is particularly passionate about including the patient groups she works with in research and healthcare decisions.

Lavvina is affiliated with The Children’s Hospital Westmead and the University of New South Wales where she is undertaking a Masters by Research, co-producing a model of genetic healthcare that aligns with the preferences of Autistic people.

Permission to Use Photos and Media

I, the undersigned, give my consent to the Angelina CASK Neurological Research Foundation Ltd and Angelina CASK Neurological Research Foundation Inc (ACNRF) to use photographs, videos, or other media featuring me, my child, or an individual under my legal guardianship (“Media Materials”).

This consent permits ACNRF to use these Media Materials for purposes such as:

  • Raising awareness of CASK-related disorders
  • Promoting ACNRF’s initiatives, campaigns, and programs
  • Sharing on ACNRF’s website, social media, newsletters, and other communication channels
  • Use in advertising, educational resources, and fundraising efforts.

I understand that these materials may be distributed publicly and may appear in print, digital, and other media formats worldwide and in perpetuity.

Terms and Conditions:

1. Usage Rights: I grant ACNRF the right to edit, adapt, or modify the Media Materials as needed for the purposes outlined above.

2. No Compensation: I acknowledge that no monetary or other compensation will be provided for the use of the Media Materials.

3. Release of Claims: I waive any rights to inspect or approve the final product and release ACNRF from any claims, liabilities, or damages related to the use of the Media Materials, including but not limited to claims of defamation, privacy, or copyright infringement.

4. Ownership Confirmation: I confirm that I have the authority to grant these rights for the provided Media Materials and that they do not infringe on the rights of any third party.

This authorisation is voluntary and may be revoked by written notice to ACNRF at any time, though I understand that materials already published may not be withdrawn.

“In some ways, that CASK-linked pathology is degenerative in nature provides a positive outlook. Because microcephaly in CASK-linked pathology progresses postnatally, there may be a temporal window when therapeutic intervention might prevent or slow further brain cell loss. Regression, even in adolescence, has also been observed in some cases of MICPCH [119], again offering the tantalizing possibility that a therapeutic approach might prevent such decline under conditions when degeneration is known to progress. The potential benefits of intervention might extend even further given that non-cell-autonomous toxicity could also affect functioning of the remaining neurons; reduction of such toxicity, especially when coupled with high-intensity rehabilitative measures [120], might offer real hope for a positive impact on functional outcomes.”   

https://www.mdpi.com/2073-4409/11/7/1131/htm